This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
Patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), and marginal zone lymphoma (MZL), planned to begin Bruton tyrosine kinase inhibitors (BTKi) treatment or who will start a new BTKi agent after a 5-day wash out period (either as a single agent or on combination with other chemotherapies), who are willing to return to Mayo Clinic for ongoing follow-up
Patients with known central nervous system (CNS) involvement of their B-cell malignancy
Patients with B-cell malignancies on BTKi treatment at Mayo Clinic.
Cohort
Prospective
Non-Interventional Study
Other interventionNon-interventional study
Incidence of major adverse cardiovascular events (MACE)
1-year MACE rates between patients with B-cell malignancies on BTKi with new or worsening HTN on optimal anti-HTN strategies will be compared with patients who do not develop HTN on BTKi.
Incidence of new and/or worsening hypertension (HTN)
Incidence of new or worsening HTN over 1 year of BTKi therapy will be recorded (defined as blood pressure (BP) increase to\>140 mmHg systolic or \> 90 mmHg diastolic).
Hemodynamic changes associated with new and/or worsening HTN
Impedance cardiography (ICG) changes from before to after BTKi initiation and anti-HTN therapy implication will be recorded to assess hemodynamic changes.
Click on the lead sponsor to view all of their trials.
